Anthony S Stein Selected Research

Hematologic Neoplasms (Hematological Malignancy)

1/2024	Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
1/2020	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
1/2020	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
1/2019	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony S Stein Research Topics

Disease

25	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2023 - 01/2005
23	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2023 - 02/2003
11	Neoplasms (Cancer) 02/2024 - 01/2005
8	Philadelphia Chromosome 01/2021 - 01/2005
7	Residual Neoplasm 02/2022 - 06/2016
6	Leukemia 01/2023 - 02/2003
5	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2023 - 11/2006
4	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 01/2019
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2024 - 04/2015
4	Cytokine Release Syndrome 06/2021 - 10/2018
4	Primary Myelofibrosis (Myelosclerosis) 01/2020 - 11/2006
2	Hypoalbuminemia 10/2022 - 01/2019
2	Infections 01/2021 - 10/2018
2	Thrombocytopenia (Thrombopenia) 01/2019 - 02/2003
1	COVID-19 01/2023
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2023
1	Blast Crisis (Blast Phase) 01/2022
1	Pathologic Complete Response 01/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Febrile Neutropenia 01/2021
1	Bites and Stings (Sting) 01/2021
1	Necrobiotic Disorders (Necrobiosis) 01/2020
1	Pulmonary Hypertension 01/2020
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2019
1	Invasive Fungal Infections 12/2019
1	Neutropenia 12/2019
1	Edema (Dropsy) 01/2019
1	Lymphoma (Lymphomas) 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Cytopenia 10/2018
1	Chromosome Aberrations (Chromosome Abnormalities) 10/2018
1	Myeloid Sarcoma (Chloroma) 08/2014
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2005
1	Fever (Fevers) 02/2003
1	Leukopenia 02/2003

Drug/Important Bio-Agent (IBA)

17	blinatumomabIBA 01/2023 - 01/2016
9	venetoclaxIBA 12/2023 - 01/2018
4	tagraxofuspIBA 02/2024 - 01/2019
4	ivosidenibIBA 01/2024 - 01/2020
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 02/2003
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2024 - 06/2018
3	Azacitidine (5 Azacytidine)FDA Link 12/2023 - 01/2019
3	enasidenibIBA 01/2021 - 01/2019
2	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 12/2023 - 01/2019
2	Inotuzumab OzogamicinIBA 01/2023 - 06/2017
2	Sirolimus (Rapamycin)FDA Link 01/2023 - 02/2010
2	Monoclonal AntibodiesIBA 01/2023 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2019
2	Clofarabine (Clolar)FDA Link 04/2015 - 03/2012
1	Interleukin-3 (Interleukin 3)IBA 12/2023
1	Diphtheria ToxinIBA 12/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	Aspartic Acid (Aspartate)FDA Link 10/2022
1	Transaminases (Aminotransferases)IBA 10/2022
1	Alanine (L-Alanine)FDA Link 10/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	CytokinesIBA 06/2021
1	EnzymesIBA 01/2021
1	fms-Like Tyrosine Kinase 3IBA 10/2020
1	Peptides (Polypeptides)IBA 01/2020
1	PNC-27IBA 01/2020
1	Cadherins (E-Cadherin)IBA 01/2020
1	Cell Surface ReceptorsIBA 12/2019
1	Alanine Transaminase (SGPT)IBA 01/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019
1	Arginine (L-Arginine)FDA Link 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2019
1	ibrutinibIBA 01/2019
1	isocitric acid (isocitrate)IBA 01/2019
1	vadastuximab talirineIBA 01/2018
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2015
1	Melphalan (Alkeran)FDA LinkGeneric 03/2012
1	Tacrolimus (Prograf)FDA LinkGeneric 02/2010
1	Methotrexate (Mexate)FDA LinkGeneric 11/2006
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 11/2006
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2005
1	Interleukin-2 (IL2)IBA 02/2003
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 02/2003

Therapy/Procedure

19	Therapeutics 01/2023 - 02/2017
10	Drug Therapy (Chemotherapy) 01/2023 - 01/2005
10	Cell Transplantation 01/2023 - 11/2006
5	Stem Cell Transplantation 12/2019 - 02/2003
4	Transplantation 01/2023 - 01/2019
4	Salvage Therapy 12/2019 - 01/2015
3	Homologous Transplantation 01/2022 - 02/2003
3	Immunotherapy 01/2019 - 02/2003
1	Lymphatic Irradiation 01/2022
1	Complementary Therapies (Alternative Medicine) 01/2019
1	Intravenous Infusions 01/2019
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Radiotherapy 08/2014
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 11/2009
1	Chemoradiotherapy 01/2005